REG - Craneware plc - Transaction in Own Shares

CranewareAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260513:nRSM0596Ea&default-theme=true

RNS Number : 0596E  Craneware plc  13 May 2026

13 May 2026

 

Craneware plc

 ("Craneware", or the "Company")

 Transaction in Own Shares and Completion of Share Buyback Programme

 

Craneware (AIM: CRW.L), a leader in healthcare financial performance
solutions, announces it has purchased the following number of its Ordinary
Shares of 1p each through Joh. Berenberg, Gossler & Co. KG, London Branch
("Berenberg") on the London Stock Exchange.

 

 Date of purchases:                                   12 May 2026
 Aggregate number of Ordinary Shares purchased:                        43,134
 Lowest price paid per share (GBp):                                   1,486.00
 Highest price paid per share (GBp):                                  1,502.46
 Volume weighted average price paid per share (GBp):                  1,501.21

The Company will hold the purchased shares in Treasury. Following the purchase
of these shares, the Company will have 34,237,148 Ordinary Shares in issue
(excluding Treasury shares), and the Company will hold 1,305,021 Ordinary
Shares in Treasury.

 

The figure of 34,237,148 represents the total voting rights in the Company and
may be used by shareholders as the denominator for calculating whether they
are required to notify their interest in, or a change to their interest in,
the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The table below contains detailed information about the purchases made as part
of the buyback programme which was announced by the Company on 16 March 2026
(the "Programme").

 

Schedule of Purchases - Individual Transactions

 

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No
596/2014 as it forms part of UK law, a full breakdown of the individual trades
made by Berenberg on behalf of the Company as part of the Programme is
detailed below:

 

 Number of ordinary shares purchased  Transaction price (GBp share)  Time of transaction (UK Time)  Transaction        Trading Venue

                                                                                                    reference number

 39,778                               1502.46                        12.05.2026 11:02:10            00067387093TRLO1   LSE
 3,085                                1486.00                        12.05.2026 11:27:24            00067387883TRLO1   LSE
 271                                  1491.00                        12.05.2026 11:38:22            00067388140TRLO1   LSE

 

 

Completion of the Share Buyback Programme

 

Following the above transaction, the Company has now utilised the $25m which
was announced as part of the FY26 Interim Results and later commenced on 16
March 2026 for the current Share Buyback Programme. In total, the Company has
repurchased 1,276,957 Ordinary Shares of 1p each, all of which will be held in
Treasury (to cover existing share options and long-term incentive plan awards
which have been granted by the Company to employees).

 

 

For further information please contact:

 

Craneware
plc
+44 (0)131 550 3100

Keith Neilson, CEO

Craig Preston, CFO

 

Alma Strategic
Communications
 
                +44 (0)20 3405 0205

Caroline Forde, Kinvara Verdon, Louisa
El-Ahwal
craneware@almastrategic.com

 

About Craneware

 

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in
healthcare financial and operational transformation, delivering cutting-edge
technologies that drive measurable impact. Our Trisus® cloud ecosystem
unifies data, revenue intelligence, margin intelligence, and advanced
analytics, enabling healthcare organizations to optimize performance, improve
financial sustainability, and drive strategic growth. As a trusted Microsoft
partner, we provide future-ready solutions-including the Best in KLAS Trisus
Chargemaster - that simplify the complexities of healthcare finance and
operations. What sets us apart is our unique combination of deep healthcare
expertise and engineering excellence, positioning us as a strategic partner
rather than just a technology provider. The Craneware Group empowers
healthcare organizations to achieve sustainable financial success while
delivering better outcomes for the communities they serve - today and in the
future. Together, we are transforming the business of healthcare.

 

Learn more at www.thecranewaregroup.com

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSEAESAFDSKEAA



            Copyright 2019 Regulatory News Service, all rights reserved